Recombinant antibodies against vascular endothelial growth factor (VEGF)

The present invention deals with recombinant polypeptide molecules related to antibodies, that specifically recognize the human Vascular Endothelial Growth Factor A (VEGF-A), and interfere with its in vitro stimulatory effects and pro-angiogenic activity in vivo . These recombinant polypeptide molec...

Full description

Saved in:
Bibliographic Details
Main Authors OSMANY GUIROLA CRUZ, MARTA AYALA AVILA, GLAY CHINEA SANTIAGO, GERTRUDIS ROJAS DORANTES, JORGE VICTOR GAVILONDO COWLEY, HUMBERTO LAMDAN ORDAS, YANELYS MORERA DIAZ, NELSON FRANCISCO SANTIAGO VISPO
Format Patent
LanguageEnglish
Published 08.05.2008
Subjects
CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
Online AccessGet full text

Cover

More Information
Summary:The present invention deals with recombinant polypeptide molecules related to antibodies, that specifically recognize the human Vascular Endothelial Growth Factor A (VEGF-A), and interfere with its in vitro stimulatory effects and pro-angiogenic activity in vivo . These recombinant polypeptide molecules affect proliferation of human endothelial cells in vitro, subcutaneous angiogenesis in mice induced by Matrigel pellets that contain VEGF-A and the growth of human tumors transplanted in nude athymic mice. Several of these moleculas prevent choroideal neovascularization in a non human primate experimental model. These molecules can be employed for passive immunotherapy in pathological entities which have in its base an abnormal increase in blood vessels, as: age-related macular degeneration (wet variant), cancer and its metastases, neovascular glaucoma, diabetic and newborn retinopathies, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, organ transplant rejection, hemangioma, angiofibroma, and others.
Bibliography:Application Number: AU20070315484